AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedNot reportedPublished in a peer-reviewed journal
Aptasensor for Myelin Basic Protein Detection in Animal Models
An aptasensor was developed to detect Myelin Basic Protein (MBP) in artificial cerebrospinal fluid (aCSF) with a limit of detection of 2 ng mL-1. It demonstrated reliable MBP detection under complex conditions.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
MBP is a potential biomarker for neurodegenerative diseases like multiple sclerosis, highlighting the aptasensor's role in early detection and monitoring.
What this does not prove
Validation in human cerebrospinal fluid (CSF) is needed to confirm effectiveness; current findings cannot directly inform human applications.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-08
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Myelin Basic Protein
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Myelin Basic Protein
- Safety
- Not reported
Original sources
- Primary evidenceLabel-Free Acoustic Wave Detection of Myelin Basic Protein for Monitoring of Neurodegenerative Disease. ↗DOI: 10.3390/bios16100564
Supporting passages (9)
publication datePublication date: 2026-10-08
interventionMyelin basic protein (MBP) is released into cerebrospinal fluid during demyelination and is therefore a promising biomarker for the detection of neurodegenerative diseases such as multiple sclerosis.
comparatorSelectivity was assessed with aptamer-free surfaces, cytochrome c, and human serum albumin (HSA) with much lower responses, while concentration-dependent MBP detection was maintained in aCSF despite the increased complexity of the matrix.
primary endpointMyelin basic protein (MBP) is released into cerebrospinal fluid during demyelination and is therefore a promising biomarker for the detection of neurodegenerative diseases such as multiple sclerosis.
findingsThe aptasensor achieved a limit of detection of 11 ng mL-1 in PBS and 2 ng mL-1 in aCSF.
limitationsWith future validation in human cerebrospinal fluid (CSF) samples, the developed biosensor has the potential to enable sensitive, label-free detection of MBP in CSF for the identification and monitoring of neurodegenerative diseases.
biological targetsMyelin basic protein (MBP) is released into cerebrospinal fluid during demyelination and is therefore a promising biomarker for the detection of neurodegenerative diseases such as multiple sclerosis.
biomarkersMyelin basic protein (MBP) is released into cerebrospinal fluid during demyelination and is therefore a promising biomarker for the detection of neurodegenerative diseases such as multiple sclerosis.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.